Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
15 avr. 2024 16h09 HE
|
Imugene Limited
Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
09 avr. 2024 12h00 HE
|
Imugene Limited
Imugene announced poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the AACR Conference.
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment
11 mars 2024 11h39 HE
|
Imugene Limited
Phase 1 trial of CD19 oncolytic virotherapy drug candidate onCARlytics cleared its first cohort within the intratumoral monotherapy arm of the study.
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
22 févr. 2024 10h10 HE
|
Imugene Limited
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio.
Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer
14 mars 2022 19h32 HE
|
Imugene Limited
New clinical trial supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA for Phase 2 clinical study (nextHERIZON) in HER-2 positive gastric or gastroesophageal junction...
Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
17 nov. 2021 01h05 HE
|
Imugene Limited
New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or...